April 2026 Research Update

This month, larger patient groups helped clarify that Bardet-Biedl syndrome often affects growth and weight, but some hormone problems may be less common than families might expect from the general description of the condition. In a pediatric clinic cohort, short stature and obesity were common by adolescence, while ongoing thyroid disease, hypogonadism, and diabetes were reported infrequently. These results add a clearer picture of what endocrine issues were actually observed in routine follow-up, while also pointing to the need for longer tracking into adulthood. [1]

In 135 genetically confirmed children and teens, obesity was reported in 77.6% of those age 15 and older, and short stature was reported in 21.1% of those 15 and older. Raised triglycerides were also common (55.5%), which connects to the day-to-day reality that weight and metabolism often need ongoing attention in Bardet-Biedl syndrome. In the same group, thyroid disease and persistent hypogonadism were uncommon, and diabetes diagnoses were reported in a small minority. [1]

For families, this adds a more grounded expectation of what was seen in one specialized pediatric clinic: weight and lipid issues were frequent, while several hormone diagnoses were less frequent in childhood and adolescence. This may matter now mainly as shared understanding of what can show up during growing years, rather than as proof of what will happen for any one person. What remains unclear is how these endocrine patterns change later in adulthood, since this report focused on pediatric and teen ages and the authors called for longer follow-up across life stages. [1]

These studies made the day-to-day picture of vision and learning in Bardet-Biedl syndrome more concrete: vision loss in BBS1 retinopathy progressed over time, and cognitive testing in a registry group showed that intellectual functioning is often reduced but varies widely. A key unifying point across both areas is that vision can strongly shape measured abilities, including non-verbal tasks that depend on seeing well. Together, this helps explain why patients can look very different from each other even with the same diagnosis, and why functional impact may not match a single test score. [2] [3]

In 48 people with BBS1-associated retinopathy followed for about 10.6 years, visual acuity worsened from a median 0.47 logMAR to 1.3 logMAR at follow-up. Retinal structure measurements also declined over time, and most tested eyes showed a rod-cone pattern of dysfunction (night and side vision affected before central vision), although there was variation. Differences in progression rate across the reported BBS1 genotypes were not significant, but one common variant (Met390Arg) was linked to older onset and later legal blindness. [2]

In a registry group of 96 people with Bardet-Biedl syndrome, the mean Full-Scale IQ was 73.5 and 38.3% scored 70 or below. Verbal skills were in the low-average range or higher for about 60%, while lower scores were partly driven by non-verbal skills that rely on vision, which is important in a condition where vision problems are common. The study also reported differences by sex (females higher on IQ and visual skills) and by genotype for some areas (BBS1 stronger verbal skills than BBS10), while adaptive functioning was similar between BBS1 and BBS10. [3]

For patients and caregivers, this month adds clearer expectations that BBS1-related vision loss can gradually worsen over many years, and that learning and thinking profiles in Bardet-Biedl syndrome are often affected but not in a single uniform way. This matters now mainly for understanding variability: a person may do relatively better in verbal areas than in vision-dependent tasks, and everyday functioning may not match a single overall IQ number. What remains uncertain is how well these group averages predict an individual person's future vision or learning needs, and the vision study focused specifically on people with BBS1. [2] [3]

This month included single-patient reports that highlight two practical issues: Bardet-Biedl syndrome can overlap with other genetic conditions and may be recognized after organ-specific testing, and setmelanotide treatment can have noticeable skin-related side effects in some people. Because these are case reports, they cannot show how common these situations are, but they help illustrate what clinicians and families sometimes encounter in real life. [4] [5]

One report described a 51-year-old woman with chronic kidney disease whose earlier Usher syndrome diagnosis prompted further evaluation after a kidney biopsy showed a specific scarring pattern (perihilar focal segmental glomerulosclerosis). Genetic testing found an SDCCAG8 variant (c.397G>T), leading to a diagnosis consistent with Bardet-Biedl type 16 and Senior-Loken type 7. The main message is that genetic testing can sometimes clarify the diagnosis when features overlap across ciliopathies (conditions involving cilia-related genes). [4]

Another report described a Bardet-Biedl syndrome patient treated with setmelanotide (a medicine used for genetic obesity in certain conditions) who developed diffuse skin darkening (hyperpigmentation). The authors also discussed other possible skin effects and noted that screening guidance is not fully defined, while suggesting baseline and annual skin examinations during treatment. This adds to the real-world safety picture by describing what one patient experienced, rather than measuring how often it happens across many patients. [5]

For families, these reports mainly add awareness rather than changing what is known from larger studies. The diagnostic case shows that kidney findings plus genetic testing can sometimes reframe an earlier diagnosis and better explain a person's combination of symptoms, which may matter when families are seeking a clear name for what is happening. The setmelanotide case adds a concrete example that skin darkening can occur and that some authors recommend regular skin checks, but it remains uncertain how often different skin effects occur because this is based on a single patient and a literature review rather than a large safety study. [4] [5]